JAAD Online
Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19

https://doi.org/10.1016/j.jaad.2020.04.097Get rights and content

Cited by (0)

Funding sources: Dr King is supported by the Ranjini and Ajay Poddar Fund for Dermatologic Diseases Research. Dr Damsky is supported by the Dermatology Foundation.

Conflicts of interest: Dr Damsky has research funding from Pfizer Inc, but Pfizer did not support this work, and is a consultant for Eli Lilly and Company. Dr King is an investigator for Concert Pharmaceuticals Inc, Eli Lilly and Company, and Pfizer Inc, is a consultant to and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, and Pfizer Inc, and is on speaker's bureaus for Pfizer Inc, Regeneron, and Sanofi Genzyme. Dr Peterson has no conflicts of interest to declare.

IRB approval status: Not applicable.

Reprints not available from the authors.

View Abstract